Vanflyta

(Quizartinib)

Vanflyta

Drug updated on 11/17/2023

Dosage FormTablet (oral; 17.7 mg or 26.5 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients newly diagnosed with acute myeloid leukemia that meets certain criteria (FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test)